SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Fallopian Tube Cancer.

ENB-105 is under development for the treatment of inflammatory bowel disease and immune checkpoint inhibitor colitis (ICI-Colitis). It is being developed based on eSTEM systems biology platform.

which will allow officials to meet with counterparts at departments and agencies ahead of the January transition of power. Pushpa 2 box office Day 13: Allu Arjun's film remains unstoppable People ...